SCHEMBL947572

SCHEMBL947572

CC(C)(C)[Si](C)(C)C(O)c1cccc(CCC(=O)N2CCOCC2)n1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ FKBP1A P62942 3/20 0.46
▸ RAB9A P51151 5/20 0.44
▸ SMN1; SMN2 Q16637 5/20 0.44
▸ NPC1 O15118 2/20 0.44
▸ MAPT P10636 2/20 0.44
▸ ALDH1A1 P00352 5/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ KDM4E B2RXH2 2/20 0.39
▸ POLB P06746 2/20 0.39
▸ HSD17B10 Q99714 2/20 0.39
▸ HPGD P15428 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ USP2 O75604 1/20 0.39
▸ HTT P42858 2/20 0.39
▸ CCNC P24863 1/20 0.38
▸ CDK8 P49336 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL947569 0.79 FKBP1A (0.43) FKBP1ARAB9ASMN1; SMN2NPC1MAPT
SCHEMBL947570 0.78 FKBP1A (0.48) FKBP1ARAB9ASMN1; SMN2NPC1MAPT
SCHEMBL1313679 0.70 FKBP1A (0.62) FKBP1ARAB9ASMN1; SMN2NPC1ALDH1A1
SCHEMBL15317672 0.66 FKBP1A (0.64) FKBP1ARAB9ASMN1; SMN2NPC1MAPT
SCHEMBL15317645 0.65 FKBP1A (0.67) FKBP1ARAB9ASMN1; SMN2NPC1MAPT
SCHEMBL8327592 0.65 FKBP1A (1.00) FKBP1ARAB9ASMN1; SMN2NPC1MAPT
SCHEMBL5501977 0.64 SIGMAR1 (0.47) ALDH1A1KDM4EPOLBTSHRHTT
SCHEMBL30461898 0.63 FKBP1A (0.72) FKBP1ARAB9ASMN1; SMN2NPC1ALDH1A1
SCHEMBL10195739 0.63 FKBP1A (0.72) FKBP1ARAB9ASMN1; SMN2ALDH1A1NPSR1
SCHEMBL3923745 0.62 MAPT (0.49) FKBP1ARAB9ASMN1; SMN2MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989446-B2 4-amino 5-cyanopyrimidine derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2011-08-02 — — US disclosed
US-20110009620-A1 4-Amino-5-cyanopyrimidine derivatives OTSUKA PHARMACEUTICAL CO., LTD. 2011-01-13 — — US disclosed
US-7834002-B2 4-amino-5-cyanopyrimidine derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-11-16 — — US disclosed
US-20080182854-A1 4-Amino-5-Cyanopyrimidine Derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-07-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110009620-A1 4-Amino-5-cyanopyrimidine derivatives ADORA2A, ADORA1, ADORA3 FKBP1A 2789/4885RAB9A 1654/4885SMN1; SMN2 4598/4885
US-20080182854-A1 4-Amino-5-Cyanopyrimidine Derivatives ADORA2A, ADORA1, ADORA3 FKBP1A 2789/4885RAB9A 1654/4885SMN1; SMN2 4598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback